scholarly journals Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson’s disease

Brain ◽  
2019 ◽  
Vol 142 (11) ◽  
pp. 3605-3620 ◽  
Author(s):  
Brónagh McCoy ◽  
Sara Jahfari ◽  
Gwenda Engels ◽  
Tomas Knapen ◽  
Jan Theeuwes
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Negative Outcomes ◽  
Choice Behaviour ◽  
Dopaminergic Medication ◽  
Future Value

McCoy et al. show that dopaminergic medication in Parkinson’s disease leads to changes in striatal signalling and in behaviour during learning, but that changes are specific to the processing of negative reinforcements. These within-patient changes are predictive of changes in future value-based choice behaviour and striatal responses.

scholarly journals Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson’s disease

2018 ◽  
Author(s):  
Brónagh McCoy ◽  
Sara Jahfari ◽  
Gwenda Engels ◽  
Tomas Knapen ◽  
Jan Theeuwes
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Learning Task ◽  
Dopamine Neurons ◽  
Negative Outcomes ◽  
Learning Differences ◽  
Dopaminergic Medication ◽  
Learning Rates ◽  
Approach Avoidance ◽  
Midbrain Dopamine

AbstractReduced levels of dopamine in Parkinson’s disease (PD) contribute to changes in learning, resulting from the loss of midbrain dopamine neurons that transmit a teaching signal to the striatum. Dopamine medication used by PD patients has previously been linked to either behavioral changes during learning itself or adjustments in approach and avoidance behavior after learning. To date, however, very little is known about the specific relationship between dopaminergic medication-driven differences during learning and subsequent changes in approach/avoidance tendencies in individual patients. We assessed 24 PD patients on and off dopaminergic medication and 24 healthy controls (HC) performing a probabilistic reinforcement learning task, while undergoing functional magnetic resonance imaging. During learning, medication in PD reduced an overemphasis on negative outcomes. When patients were on medication, learning rates were lower for negative (but not positive) outcomes and concurrent striatal BOLD responses showed reduced prediction error sensitivity. Medication-induced shifts in negative learning rates were predictive of changes in approach/avoidance choice patterns after learning, and these changes were accompanied by striatal BOLD response alterations. These findings highlight dopamine-driven learning differences in PD and provide new insight into how changes in learning impact the transfer of learned value to approach/avoidance responses in novel contexts.

scholarly journals Implications of dopaminergic medication withdrawal in Parkinson’s disease

2021 ◽  
Author(s):  
J. Koschel ◽  
K. Ray Chaudhuri ◽  
L. Tönges ◽  
M. Thiel ◽  
V. Raeder ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Medication ◽  
Medication Withdrawal

scholarly journals Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Phase I Clinical Trials ◽  
Preclinical Models ◽  
Preclinical Development ◽  
Dopaminergic Medication ◽  
Gene Therapies ◽  
Advanced Therapies ◽  
New Phase

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

scholarly journals Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135287 ◽  
Author(s):  
Wiebke Grashorn ◽  
Odette Schunke ◽  
Carsten Buhmann ◽  
Katarina Forkmann ◽  
Sabrina Diedrich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pain Modulation ◽  
Conditioned Pain Modulation ◽  
Dopaminergic Medication

scholarly journals Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia

2015 ◽  
Vol 3 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Tareq Sawan ◽  
Mary Louise Harris ◽  
Christopher Kobylecki ◽  
Laura Baijens ◽  
Michel van Hooren ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lung Function ◽  
Lung Function Testing ◽  
Dopaminergic Medication ◽  
Function Testing

scholarly journals Differential dopaminergic modulation of spontaneous cortico-subthalamic activity in Parkinson’s disease

2020 ◽  
Author(s):  
Abhinav Sharma ◽  
Diego Vidaurre ◽  
Jan Vesper ◽  
Alfons Schnitzler ◽  
Esther Florin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Beta Activity ◽  
Beta Band ◽  
Time Resolved ◽  
Functional Roles ◽  
Dopaminergic Medication ◽  
Physiological Processes ◽  
Motor Network ◽  
Theta Frequency

AbstractPathological oscillations including elevated beta activity in the subthalamic nucleus (STN) and between STN and cortical areas are a hallmark of neural activity in Parkinson’s disease (PD). Oscillations also play an important role in normal physiological processes and serve distinct functional roles at different points in time. We characterised the effect of dopaminergic medication on oscillatory whole-brain networks in PD in a time-resolved manner by employing a hidden Markov model on combined STN local field potentials and magnetoencephalography (MEG) recordings from 17 PD patients. Dopaminergic medication led to communication within the medial and orbitofrontal cortex in the delta/theta frequency range. This is in line with deteriorated frontal executive functioning as a side effect of dopamine treatment in Parkinson’s disease. In addition, dopamine caused the beta band activity to switch from an STN-mediated motor network to a frontoparietal-mediated one. In contrast, dopamine did not modify locally-originating STN oscillations in PD. STN–STN synchrony emerged both on and off medication. By providing electrophysiological evidence for the differential effects of dopaminergic medication on the discovered networks, our findings open further avenues for electrical and pharmacological interventions in PD.

scholarly journals A survey into the influence of dopaminergic drug exposure on ‘sense of presence’ symptoms in patients with parkinson's disease

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S279-S280
Author(s):  
Emma Padfield ◽  
Hannah Potticary ◽  
Tim Segal
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Regression Analysis ◽  
Drug Exposure ◽  
Drug Dosage ◽  
Equivalent Dose ◽  
Dopaminergic Medication ◽  
Dopaminergic Drug ◽  
Sense Of Presence ◽  
The Relationship

AimsThe first objective was to estimate prevalence of sense of presence (SoP) experiences in patients with Parkinson's Disease (PD), including whether onset was prior to or after commencing dopaminergic medication. The second objective was to explore the relationship between frequency of SoP experiences and dopaminergic drug, drug dosage and length of drug exposure. The experimental hypothesis was that SoP symptoms in PD would present more frequently in patients treated longer and with higher dopaminergic drug doses.BackgroundPD is a debilitating neurodegenerative disorder. Psychiatric symptoms are common and associated with impaired quality of life and higher treatment costs. PD psychosis often starts with ‘minor hallucinations’, the most common being a false ‘sense of presence’ (SoP), the vivid sensation that someone else is nearby when nobody is there. SoP symptoms typically do not cause significant distress but may act as a prognostic marker for future severe psychosis and may prompt alteration of treatment or reduction in dopaminergic drug dosage. This study aimed to extend prior research by characterizing SoP further and investigating the link with dopaminergic medication.MethodThis was a retrospective, cross-sectional study. Twenty-one patients diagnosed with PD completed a questionnaire to identify presence of SoP symptoms, duration of symptoms, timing of onset related to dopaminergic treatment and the frequency of symptoms in relation to current levodopa equivalent dose (LED). Descriptive frequencies were compared using a two-tailed t-test. Multiple regression analysis was conducted to assess the relationship between frequency of SP experiences, levodopa equivalent dose and length of drug exposure.ResultSixteen of twenty-one patients reported experiencing SoP symptoms. Patients who had not experienced SoP symptoms had a significantly lower LED than those who had experienced these symptoms. There were no other significant differences between the groups. No statistical significance was shown on regression analysis; however our study was not adequately powered for the regression analysis as the number of participants was too low.ConclusionThis study confirms that SoP symptoms are common among patients with PD and supports a correlation between the total daily equivalent dose of levodopa and SoP symptoms. It does not provide evidence for a temporal relationship between onset of SoP symptoms and duration of dopaminergic treatment. The study was insufficiently powered and a larger study is required to investigate further.

scholarly journals Dopaminergic Medication-Related Repetitive Behaviors in Parkinson’s Disease

2008 ◽  
Vol 1 (2) ◽  
pp. 101-103 ◽  
Author(s):  
Jong Sam Baik ◽  
Sang Won Han ◽  
Jeong Yeon Kim ◽  
Jae Hyeon Park
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Repetitive Behaviors ◽  
Dopaminergic Medication

The reach-to-grasp movement in Parkinson’s disease before and after dopaminergic medication

2000 ◽  
Vol 38 (1) ◽  
pp. 46-59 ◽  
Author(s):  
U. Castiello ◽  
K.M.B. Bennett ◽  
C. Bonfiglioli ◽  
R.F. Peppard
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Reach To Grasp ◽  
Dopaminergic Medication ◽  
Before And After
Sign in / Sign up

Export Citation Format

Share Document